Maxalt

For the acute treatment of migraine in adults, the standard recommended dose of rizatriptan is either 5 mg or 10 mg. Clinical trials have shown that the 10 mg dose may provide greater efficacy but also carries a slightly higher risk of side effects.

• Initial Dose: 5 mg or 10 mg taken at the onset of the migraine.
• Repeat Dosing: If the migraine returns after initial relief, a second dose may be taken. However, you must wait at least 2 hours between doses.
• Maximum Dose: Do not exceed 30 mg within a 24-hour period. Taking more than the recommended amount can lead to serious cardiovascular complications or 'medication overuse headache.'

Rizatriptan is approved for pediatric patients aged 6 to 17 years. The dosage is strictly weight-based to ensure safety and efficacy:

• Patients weighing less than 40 kg (88 lbs): A single 5 mg dose is recommended. The safety of a second dose in a 24-hour period has not been established for this weight group.
• Patients weighing 40 kg (88 lbs) or more: A single 10 mg dose is recommended. Similar to the lower weight group, the safety of repeat dosing within 24 hours has not been fully evaluated in pediatric clinical trials.

Renal Impairment

In patients with mild to moderate renal impairment, rizatriptan should be used with caution. In patients on dialysis, the clearance of rizatriptan is reduced. Healthcare providers typically recommend using the 5 mg strength as the starting dose for patients with significant kidney issues.

Hepatic Impairment

For patients with mild to moderate hepatic (liver) insufficiency, the plasma concentrations of rizatriptan can be increased. A 5 mg dose is generally recommended as the starting point. Rizatriptan has not been well-studied in patients with severe hepatic impairment (Child-Pugh score >9).

Elderly Patients

Pharmacokinetic studies in the elderly (over 65) show similar profiles to younger adults. However, because elderly patients are more likely to have underlying cardiovascular conditions, healthcare providers must perform a thorough cardiac evaluation before prescribing rizatriptan to this population.

• Conventional Tablets: Swallow the tablet whole with water. Do not crush or chew the tablet, as this can affect the absorption rate.
• Orally Disintegrating Tablets (ODT): Leave the tablet in its blister pack until you are ready to take it. With dry hands, peel open the foil and place the tablet on your tongue. It will dissolve rapidly and can be swallowed with saliva. No water is necessary.
• Timing: Take the medication as soon as the migraine symptoms begin. It is not effective if taken during the 'aura' phase (visual disturbances) before the actual pain starts; wait for the headache phase to begin.
• Food: Rizatriptan can be taken with or without food. However, taking it on an empty stomach may lead to a slightly faster onset of action.

Since rizatriptan is taken 'as needed' for acute attacks, there is no regular dosing schedule. If you experience a migraine and forget to take your medication, take it as soon as you remember. Do not take two doses at once to make up for a missed opportunity.

Signs of a rizatriptan overdose may include severe hypertension (high blood pressure), dizziness, fainting, or a slow heartbeat (bradycardia). In the event of a suspected overdose, seek emergency medical attention immediately. Treatment is symptomatic and supportive, often requiring cardiac monitoring for at least 15 to 20 hours due to the drug's effects on the cardiovascular system.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Overusing triptans can lead to chronic daily headaches.

Most patients tolerate rizatriptan well, but some side effects are relatively common. These are usually mild and transient, resolving as the medication wears off.

• Somnolence (Drowsiness): This is the most frequently reported side effect. Patients may feel a strong urge to sleep or feel 'foggy' for several hours after taking the dose.
• Dizziness: A sensation of lightheadedness or spinning is common, especially when moving from a sitting to a standing position.
• Fatigue and Asthenia: A general feeling of weakness or lack of energy often follows the resolution of the migraine.
• Paresthesia: Patients may experience tingling, prickling, or 'pins and needles' sensations, particularly in the hands, feet, or face.

• Nausea and Dry Mouth: While nausea is often a symptom of the migraine itself, rizatriptan can occasionally exacerbate it or cause a dry, parched feeling in the mouth.
• Chest/Neck/Jaw Tightness: This is a classic 'triptan sensation.' It is usually not cardiac in origin but can be distressing. It feels like a heavy pressure or squeezing in the chest or throat area.
• Flushing: A sudden feeling of warmth or redness in the face and neck.
• Hypesthesia: A decrease in sensitivity to touch or pressure in certain areas of the body.

• Palpitations: Feeling like the heart is skipping a beat or racing.
• Tinnitus: Ringing in the ears.
• Visual Disturbances: Blurred vision or temporary changes in sight beyond the initial migraine aura.
• Syncope: Fainting or temporary loss of consciousness.

> Warning: Stop taking Rizatriptan and call your doctor immediately if you experience any of these.

• Myocardial Infarction (Heart Attack): Symptoms include crushing chest pain, shortness of breath, and pain radiating to the jaw or left arm. This is rare but possible due to coronary artery vasospasm.
• Stroke or TIA: Sudden numbness on one side of the body, slurred speech, or facial drooping. Triptans can cause cerebrovascular constriction.
• Serotonin Syndrome: A potentially life-threatening condition characterized by agitation, hallucinations, rapid heartbeat, fever, muscle stiffness, and loss of coordination. This usually occurs when rizatriptan is combined with other serotonergic drugs (like SSRIs or SNRIs).
• Gastrointestinal Ischemia: Severe abdominal pain and bloody diarrhea caused by reduced blood flow to the intestines.
• Peripheral Vascular Ischemia: Numbness or coldness in the extremities, often accompanied by a 'blue' tint to the skin (Raynaud's-like symptoms).
• Anaphylaxis: Severe allergic reaction including swelling of the face, tongue, or throat, and difficulty breathing.

• Medication Overuse Headache (MOH): Using rizatriptan more than 10 days per month can lead to a cycle where the medication actually causes more frequent headaches. This is often referred to as 'rebound headache.'
• Cardiovascular Stress: Frequent use in patients with borderline hypertension may lead to chronic elevations in blood pressure.

No FDA black box warnings are currently issued for Rizatriptan. However, the FDA maintains strict 'Contraindications' for patients with existing cardiovascular disease, which serve as the highest level of warning for this drug class.

Report any unusual symptoms to your healthcare provider. If you notice a change in the pattern of your headaches, it is vital to discuss this with a specialist.

Rizatriptan is a potent vasoconstrictor (vessel-narrower). While it is designed to target vessels in the brain, it can affect blood vessels throughout the body. Therefore, it must be used with extreme caution in individuals with any history of vascular disease. Patients should be screened for cardiovascular risk factors (hypertension, high cholesterol, smoking, obesity, diabetes, strong family history of heart disease) before the first dose is prescribed.

No FDA black box warnings for Rizatriptan. Unlike some other classes of drugs, the safety profile of triptans is managed through contraindications and 'Warnings and Precautions' sections in the prescribing information.

• Coronary Artery Vasospasm: Rizatriptan can cause the arteries supplying the heart to tighten. In patients with 'silent' heart disease, this can trigger a heart attack. If you experience any chest pain, do not take another dose and seek medical evaluation.
• Cerebrovascular Events: There have been reports of stroke, cerebral hemorrhage, and other vascular events following triptan use. These events are most common in patients who were already at risk for stroke.
• Hypertension: Rizatriptan can cause a transient but significant increase in blood pressure. It is contraindicated in patients with uncontrolled hypertension. Even in patients with controlled high blood pressure, monitoring is advised.
• Serotonin Syndrome: Because rizatriptan increases serotonin activity, combining it with antidepressants like Zoloft (sertraline), Prozac (fluoxetine), or Effexor (venlafaxine) increases the risk of serotonin syndrome. Symptoms include mental status changes and neuromuscular hyperactivity.
• Medication Overuse Headache: If you find yourself needing rizatriptan more than twice a week, you may be at risk for medication overuse headache. This condition requires a supervised withdrawal from the medication.

• Cardiac Evaluation: For patients with multiple cardiovascular risk factors who are deemed appropriate for rizatriptan, the first dose should ideally be administered in a medically supervised setting with an EKG (electrocardiogram) performed.
• Blood Pressure: Regular monitoring of blood pressure is recommended for all patients using triptans chronically.
• Liver/Kidney Function: Periodic blood tests may be required for patients with known hepatic or renal impairment to ensure the drug is being cleared effectively.

Because rizatriptan frequently causes somnolence (drowsiness) and dizziness, patients should not drive, operate heavy machinery, or engage in hazardous activities until they are certain how the medication affects them. The migraine itself can also impair coordination and reaction time.

Alcohol is a known migraine trigger for many people. Additionally, alcohol can increase the sedative effects (drowsiness) of rizatriptan. It is generally advised to avoid alcohol during a migraine attack and while the medication is in your system.

There is no physical 'withdrawal' syndrome from stopping rizatriptan if it is used occasionally. However, if it has been overused (daily or near-daily), stopping it may cause a temporary 'rebound' worsening of headaches for several days. This should be managed under the guidance of a neurologist.

> Important: Discuss all your medical conditions with your healthcare provider before starting Rizatriptan, especially any history of heart, liver, or kidney disease.

• MAO Inhibitors (MAOIs): Drugs like phenelzine, tranylcypromine, and isocarboxazid inhibit the enzyme (MAO-A) that breaks down rizatriptan. Taking these together can increase rizatriptan levels by up to 400%, leading to dangerous toxicity. You must wait at least 14 days after stopping an MAOI before taking rizatriptan.
• Ergotamine-type Medications: Drugs like Cafergot or D.H.E. 45 also cause vasoconstriction. Using them within 24 hours of rizatriptan can cause additive, prolonged vasospastic reactions (severe narrowing of blood vessels).
• Other Triptans: Do not use rizatriptan within 24 hours of using another triptan (e.g., sumatriptan, zolmitriptan) due to the risk of additive cardiovascular effects.

• Propranolol: This beta-blocker is often used for migraine prevention. Propranolol increases the plasma concentration (AUC) of rizatriptan by approximately 70%. If you are taking propranolol, your rizatriptan dose must be limited to 5 mg, and you should not exceed 15 mg in 24 hours.
• SSRIs and SNRIs: Selective Serotonin Reuptake Inhibitors (e.g., escitalopram) and Serotonin-Norepinephrine Reuptake Inhibitors (e.g., duloxetine) increase the risk of Serotonin Syndrome. While many patients take these together safely, they must be educated on the warning signs of serotonin toxicity.

• Cimetidine: This heartburn medication can slightly increase the levels of many drugs, though its effect on rizatriptan is generally considered minor.
• CYP3A4 Inhibitors: While rizatriptan is primarily metabolized by MAO-A, minor pathways involve CYP3A4. Strong inhibitors like ketoconazole or clarithromycin may theoretically increase levels, though clinical significance is low.

• High-Fat Meals: Consumption of a high-fat meal does not change the total amount of rizatriptan absorbed, but it can delay the time it takes for the drug to work by about an hour. For the fastest relief, take on an empty stomach.
• Caffeine: Some migraineurs find caffeine helpful, but it can also increase heart rate and blood pressure, potentially compounding the cardiovascular effects of rizatriptan.

• St. John's Wort: This herbal supplement has serotonergic properties and may increase the risk of serotonin syndrome when combined with triptans.
• 5-HTP / L-Tryptophan: These precursors to serotonin can also increase the risk of serotonin toxicity.
• Ginkgo Biloba: May have mild anti-platelet effects; use caution if taking other medications that affect blood flow.

Rizatriptan is not known to significantly interfere with common laboratory tests (such as blood glucose, cholesterol, or liver enzymes). However, always inform the lab technician of all medications you are taking.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is the only way to prevent dangerous interactions.

In the following scenarios, rizatriptan must NEVER be used because the risks of life-threatening complications far outweigh the benefits:

• Ischemic Heart Disease: This includes a history of myocardial infarction (heart attack), angina pectoris (chest pain), or documented silent ischemia. Rizatriptan's vasoconstrictive properties can cause a total blockage of the coronary arteries.
• Coronary Artery Vasospasm: Including Prinzmetal’s variant angina. These patients have hyper-reactive arteries that may spasm severely in response to triptans.
• Wolff-Parkinson-White (WPW) Syndrome: Or other arrhythmias associated with cardiac accessory conduction pathway disorders. Triptans have been linked to serious heart rhythm disturbances in these patients.
• History of Stroke or TIA: Transient Ischemic Attacks (mini-strokes) or full strokes are absolute contraindications due to the risk of further cerebrovascular constriction.
• Peripheral Vascular Disease (PVD): Including ischemic bowel disease. Narrowing of the vessels in the legs or gut can lead to gangrene or tissue death.
• Uncontrolled Hypertension: Patients with a baseline blood pressure that is high and not managed with medication are at risk for hypertensive crisis.
• Basilar or Hemiplegic Migraine: These specific types of migraine involve neurological deficits that mimic strokes. Triptans are not safe for these conditions.

Conditions requiring a careful risk-benefit analysis and 'first-dose' monitoring:

• Postmenopausal Women and Men over 40: Due to the higher statistical likelihood of undiagnosed heart disease.
• Smokers: Tobacco use significantly increases vascular risks.
• Controlled Hypertension: While not an absolute contraindication, these patients require close monitoring.
• Severe Renal or Hepatic Impairment: Dose adjustments and caution are required.

Patients who have had a severe allergic reaction (anaphylaxis or angioedema) to other triptans (like sumatriptan or almotriptan) should use rizatriptan with extreme caution, as there is a possibility of cross-sensitivity between members of the triptan class.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Rizatriptan. Be honest about your heart health and family history.

Rizatriptan is classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus (such as decreased body weight and decreased survival of offspring), but there are no adequate and well-controlled studies in humans.

• Trimester-Specific Risks: Most experts suggest avoiding triptans during the first trimester unless the benefit clearly outweighs the risk.
• Clinical Guidance: If a patient becomes pregnant while taking rizatriptan, they should contact their neurologist immediately. Non-pharmacological treatments or older, better-studied medications (like acetaminophen) are often preferred during pregnancy.

Studies in rats have shown that rizatriptan is excreted in milk at concentrations 5 times higher than in the mother's plasma. It is not known whether rizatriptan is excreted in human breast milk.

• Precaution: To minimize exposure to the infant, some healthcare providers suggest 'pumping and discarding' breast milk for 24 hours after taking a dose of rizatriptan.
• Monitoring: If breastfeeding, monitor the infant for signs of drowsiness or poor feeding.

Rizatriptan is approved for children aged 6 to 17 years. It is one of the most rigorously studied triptans in the pediatric population.

• Efficacy: Clinical trials demonstrated that rizatriptan was significantly more effective than placebo in achieving 'pain-free' status at 2 hours in children.
• Safety: The side effect profile in children is similar to adults, with somnolence being the most common. It is NOT approved for children under the age of 6.

Clinical studies of rizatriptan did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects.

• Pharmacokinetics: In elderly subjects, the pharmacokinetics are similar to younger adults.
• Vascular Risk: The primary concern in the elderly is the higher prevalence of coronary artery disease and hypertension. A thorough cardiac workup is mandatory for geriatric patients before starting rizatriptan.

• Mild to Moderate: Use with caution. The 5 mg dose is preferred.
• Severe/Dialysis: Rizatriptan clearance is significantly reduced in patients on hemodialysis. Use is generally discouraged or restricted to very low doses under specialist supervision.

• Mild to Moderate: The plasma concentration of rizatriptan is increased by about 30%. A 5 mg dose is the recommended maximum starting dose.
• Severe: Rizatriptan has not been studied in severe hepatic impairment and should be avoided.

> Important: Special populations require individualized medical assessment. Never share your migraine medication with others, especially children or the elderly.

Rizatriptan is a selective agonist for the 5-HT1B and 5-HT1D receptors. These receptors are found on the smooth muscle of intracranial blood vessels and on the presynaptic terminals of the trigeminal nerve.

1. 1Vasoconstriction: Activation of 5-HT1B receptors on the walls of cephalic blood vessels leads to vasoconstriction, reversing the vasodilation that occurs during a migraine.
2. 2Neuropeptide Inhibition: Activation of 5-HT1D receptors on the trigeminal nerve endings inhibits the release of calcitonin gene-related peptide (CGRP), a potent vasodilator and mediator of pain and inflammation.
3. 3Central Inhibition: Rizatriptan may also act on the trigeminal nucleus caudalis to inhibit pain transmission within the central nervous system.

• Onset of Action: Patients often report relief starting within 30 to 60 minutes.
• Duration: The therapeutic effect typically lasts for the duration of the migraine attack, though 10-20% of patients may experience a 'recurrence' within 24 hours.
• Dose-Response: There is a clear dose-response relationship between 5 mg and 10 mg, with 10 mg providing superior pain-free rates but higher incidence of dizziness and somnolence.

| Parameter | Value |

|---|---|

| Bioavailability | ~45% |

| Protein Binding | ~14% |

| Half-life | 2 - 3 hours |

| Tmax (Tablet) | 1 hour |

| Tmax (ODT) | 1.3 hours |

| Metabolism | MAO-A (Primary) |

| Excretion | Renal 82%, Fecal 12% |

• Molecular Formula: C15H19N5 (as base)
• Molecular Weight: 269.34 g/mol (base); 391.47 g/mol (benzoate salt)
• Solubility: Highly soluble in water.
• Structure: It is a tryptamine derivative, structurally related to the neurotransmitter serotonin (5-HT).

Rizatriptan belongs to the 'Triptan' class of medications. It is specifically a second-generation triptan, designed for better bioavailability and faster onset than the first-generation sumatriptan. Other drugs in this class include almotriptan, eletriptan, frovatriptan, naratriptan, sumatriptan, and zolmitriptan.